Ligand to Report Third Quarter 2019 Results on November 5th

About this update from Ligand Pharmaceuticals Incorporated

[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.\n\n\nThird Quarter 2019 Earnings Call\n\n\n\n\nWhat:\n\n\n \n\n \n\n\n\nLigand conference call to discuss financial results and provide general business updates\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n\n\nWhen:\n\n\n \n\n \n\n\n\nTuesday, November 5, 2019\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n\n\nTime:\n\n\n \n\n \n\n\n\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n \n\n \n\n\n\n(833) 591-4752 within the U.S.\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n(720) 405-1612 outside the U.S.\n\n\n\n\n\n \n\n\n \n\n \n\n\n\nConference ID - 6093759\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n \n\n \n\n\n\nLive conference call webcast and replay accessible at www.ligand.com\n\n\n\n\n\nAbout Ligand Pharmaceuticals\n\n\nLigand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships w...

More updates from Ligand Pharmaceuticals Incorporated